연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
2067. Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells.
Kim S1, Kim H2, Jo DH3, Kim JH4, Kim SR5, Kang D5, Hwang D6, Chung J7.
Methods. 2018 Oct 4. pii: S1046-2023(18)30161-0. doi: 10.1016/j.ymeth.2018.10.002. [Epub ahead of print]
Link
2066. An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.
Jin J1,2, Park G3,4, Park JB4,5, Kim S1,3, Kim H1,3,6, Chung J7,8,9.
Exp Mol Med. 2018 May 24;50(5):67. doi: 10.1038/s12276-018-0096-z.
Link
2065. The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals.
Jin J1, Park C2, Cho SH2, Chung J3.
Biochem Biophys Res Commun. 2018 Feb 12;496(3):846-851. doi: 10.1016/j.bbrc.2018.01.141. Epub 2018 Jan 31.
Link
2064. β-Adrenergic receptor agonists attenuate pericyte loss in diabetic retinas through Akt activation.
Yun JH1, Jeong HS1, Kim KJ1, Han MH1, Lee EH2, Lee K3, Cho CH1,4,5.
FASEB J. 2018 May;32(5):2324-2338. doi: 10.1096/fj.201700570RR. Epub 2017 Dec 21.
Link
2063. Retinal pigment epithelium-derived transforming growth factor-β2 inhibits the angiogenic response of endothelial cells by decreasing vascular endothelial growth factor receptor-2 expression.
Jeong HS1,2, Yun JH1, Lee DH1,2, Lee EH3, Cho CH1,2,4.
J Cell Physiol. 2019 Apr;234(4):3837-3849. doi: 10.1002/jcp.27156. Epub 2018 Sep 7.
Link
2062. Interaction between microglia and retinal pigment epithelial cells determines the integrity of outer blood-retinal barrier in diabetic retinopathy.
Jo DH1, Yun JH2, Cho CS1, Kim JH1, Kim JH1,3,4, Cho CH2,3,5.
Glia. 2018 Nov 16. doi: 10.1002/glia.23542. [Epub ahead of print]
Link
2061. [18F]FEDAC as a targeting agent for activated macrophage in DBA/1 mice with collagen-induced arthritis: comparison with [18F]FDG
Chung SJ, Yoon HJ, Cheon GJ, Youn H, Kim MJ, Xie L, Lee YS, Jeong JM, Chung JK, Kang KW, Zhang MR
J Nucl Med 2018; 59:839-845
Link
2060. Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes
Park S, Paeng JC, Kang CH, Cheon GJ, Kang KW, Chung JK, Lee DS
Eur J Nucl Med Mol Imaging 2018; 45:1317-1328
Link
2059. In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs).
Chung SJ1, Youn H2, Jeong EJ3, Park CR4, Kim MJ3, Kang KW5, Zhang MR6, Cheon GJ7.
Biochem Biophys Res Commun. 2018 Nov 17;506(1):216-222. doi: 10.1016/j.bbrc.2018.10.083. Epub 2018 Oct 19.
Link
2058. Prevalence of Participating in Physical Activity From 2 Korean Surveillance Systems: KNHANES and KCHS.
Park J, Shin A, Lee M, Choi J, Song M, Kim Y, Lee JK, Kang D, Choi JY.
J Phys Act Health. 2018 Oct 1;15(10):763-773. doi: 10.1123/jpah.2017-0428. Epub 2018 Aug 19.
Link